Table 2.
RI and RSV-positive hospitalizations across group 2 subpopulations
| Total | Hospitalized | Tested | Positive | RI hospitalization rate | RSV hospitalization rate | |
|---|---|---|---|---|---|---|
| Cardiac | 22 | 2 | 2 | 1 | 9.1 | 4.55 |
| Pulmonary | 127 | 11 | 10 | 2 | 8.7 | 1.73 |
| Neuromuscular | 78 | 14 | 13 | 5 | 17.9 | 6.90 |
| Other | 163 | 14 | 11 | 1 | 8.6 | 0.78 |
| Multiple | 57 | 8 | 7 | 1 | 14.0 | 2.01 |
| Immunocompromised | 17 | 2 | 1 | 1 | 11.8 | 11.8 |
| Airway anomalies | 178 | 18 | 15 | 4 | 10.1 | 2.70 |
| Down syndrome | 193 | 13 | 11 | 3 | 6.7 | 1.84 |
| Cystic fibrosis | 117 | 4 | 3 | 1 | 3.4 | 1.14 |
| Total group 2 | 952 | 86 | 73 | 19 | 9.0 | 2.35 |
Cohort with preexisting medical illnesses who are not currently approved for RSV prophylaxis